Trv Gp V LLC Acquires Shares of 950,800 Maze Therapeutics, Inc. (NASDAQ:MAZE)

Key Points

• Trv Gp V LLC acquired 950,800 shares of Maze Therapeutics for approximately $10.5 million, making it the third largest position in their portfolio.
• Shares of Maze Therapeutics saw a decline of 1.8% and are currently trading at $14.25, with a yearly high of $19.19.
• Maze Therapeutics reported a loss of ($1.15) EPS for the recent quarter, missing analysts' expectations, and has a consensus rating of "Buy" with a target price of $25.60.

Trv Gp V LLC bought a new stake in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 950,800 shares of the company's stock, valued at approximately $10,468,000. Maze Therapeutics accounts for about 8.4% of Trv Gp V LLC's portfolio, making the stock its 3rd biggest position. Trv Gp V LLC owned about 2.17% of Maze Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in MAZE. New York State Common Retirement Fund bought a new position in Maze Therapeutics in the 1st quarter valued at $25,000. Bank of New York Mellon Corp purchased a new stake in shares of Maze Therapeutics during the first quarter valued at $190,000. Charles Schwab Investment Management Inc. bought a new position in shares of Maze Therapeutics in the first quarter worth about $796,000. Bessemer Group Inc. purchased a new position in Maze Therapeutics in the 1st quarter worth about $5,305,000. Finally, Harvard Management Co. Inc. bought a new stake in Maze Therapeutics during the 1st quarter valued at about $7,019,000.

Maze Therapeutics Trading Down 1.8%

Shares of Maze Therapeutics stock opened at $14.25 on Thursday. The business's 50-day simple moving average is $13.82. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $19.19.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.39).

Analyst Ratings Changes

MAZE has been the subject of several research reports. Wedbush began coverage on shares of Maze Therapeutics in a research report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price objective for the company. HC Wainwright initiated coverage on Maze Therapeutics in a report on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 price target for the company. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Maze Therapeutics has a consensus rating of "Buy" and a consensus target price of $25.60.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.